Vac_99_2024 - Predoctoral Researcher

Your mission The Josep Carreras Leukemia Research Institute (IJC) is a comprehensive cancer research center dedicated to researching and promoting innovation in the epidemiological, preventive, clinical, translational and basic aspects of leukemia and other hematological malignancies, with the objective end of finding a cure for these diseases.
It was created in 2010, and since then, it has experienced exponential growth.
The IJC is also part of the network of Research Centers of Excellence of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation and Universities in 2024.
Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC) In addition, the IJC is one of the centers integrated into the accreditation of the Germans Trias i Pujol Research Institute (IGTP) as an Accredited Health Research Institute (IIS) by the Health Institute Charles III (ISCIII).
The IJC main headquarters is located within the Can Ruti Biomedical Campus, together with other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services.
The IJC has six headquarters integrated into reference hospitals: Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Trueta, Hospital del Mar and Hospital San Joan de Déu.
This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.
We are seeking  a Predoctoral Researcher  for our institute.
RESEARCH DESCRIPTION   Aggressive B-cell lymphomas are clinically and pathologically diverse and reflect multiple pathways of transformation involving, among others, oncogenic signaling, lymphoma-stroma crosstalk and intrinsic protein homeostasis.
Alterations in these highly regulated processes play a key role in the progression of the malignant clone and correlate with a high failure rate in treatment protocols.
In the last decade, new therapies applied to the treatment of B-cell lymphoma have significantly improved the overall survival of these patients, but at present no drug can cure these diseases.
At the origin of the gap between promising preclinical results and failure in clinical phase II/III, conventional preclinical models lack predictive value in the main trials carried out in these cancer subtypes.
For the design of new therapies more selective and more suited to the biology of these lymphomas, our team focuses on the characterization of new drug targets and on the bench-to-bedside translation of innovative therapeutic strategies, using cutting-edge experimental models of diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and transformed follicular lymphoma (tFL).
Please also visit our unit webpage:  https://www.carrerasresearch.org/en/research/lymphoma-translational-group .
This contract is financed by the Department of Research and Universities of the Generalitat de Catalunya, Agency for Management of University Research Grants (AGAUR), within the framework of the call "Grants to support the scientific activity of the Research Groups of Catalonia (SGR-Cat-2021)", Research group Personalized therapies and molecular bases of aggressive B-cell lymphomas (TRANSFORB), reference 2021 SGR 01535.
MAIN RESPONSIBILITIES   To participate in a research project centered on the design, synthesis and biological validation of a proteolysis targeting chimera (PROTAC) library targeting a specific oncogenic pathway in malignant B cells.
To setup a collection of in vitro (3D spheroids) and in vivo (cell line- and patient-derived mice and chicken embryo chorioallantoic membranes (CAM) xenografts) for efficacy and safety studies.
To develop analytical tools (multiomics, cell-based assays, in vitro/vivo imaging) To undertake experimental design, data analysis and interpretation.
Your profile WHAT WE NEED   We are looking for a highly-motivated scientist with a Master degree to work in the fields of tumor preclinical modelling, drug development and mutiomics data integration in hematological cancers.
The successful candidate will have the opportunity to build her/his professional skills at the intersection of distinct fields, including oncology, immunology, computational science and drug development.
Her/his work will help in advancing the development of new therapeutic strategies in aggressive B-cell lymphoma and will have a strong impact in personalized medicine.
The ideal candidate is a creative mind and has a pharmacy background with experience in functional biological assays.
Committed scientist with experience in anticancer drug design, cell culture, cell-based assays, cellular and molecular biology.
Previous experience in computational chemistry will be positively valuated.
A high level of motivation and interest in biomedical research.
Good communication skills.
Being open-minded, flexible, and collaborative.
Good communication skills in English and can work independently.
Work ethics, values, team player, independent thinking, enthusiasm, proactivity.
Why us?
WHAT WE OFFER   1 Year Temporary Contract Full time contract.
The opportunity to contribute to cutting-edge translational research projects in the stimulating environment of the Josep Carreras Leukaemia Research Institute.
The stimulating environment of the Barcelona metropolitan area.
Opportunity for professional growth in an advanced research environment.
How to apply?
DEADLINE FOR APPLICATIONS Please submit your application by 23/12/2024 About us What makes us different?
The mission of the Josep Carreras Institute is to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of cancer, with a special emphasis on leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases.
The IJC's vision is to be a world-class reference and excellent research multicampus that contributes to the improvement of results, and the cure of patients affected by leukemia and other malignant hemopathies, through innovation, sustainability, social responsibility, talent, and professional experience.
HR Excellence In 2019, IJC was honored with the "Human Resources Excellence in Research Award" by the European Commission, recognizing  the alignment of our human resources policies with the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers.
The Human Resources Strategy for Researchers (HRS4R) guides research centers of excellence in implementing and upholding these standards within their policies, emphasizing training, professional development, and mobility opportunities.
The IJC's commitment to these values and principles strengthens our internal policies and ensures that our members have the optimal conditions and environment for their professional development.
The IJC is an equal opportunity employer.
We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, or other legally protected characteristics.